Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center

OBJECTIVE: Studies have demonstrated improved ovarian cancer survival with the administration of a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy following optimal cytoreduction. Despite this, IV/IP chemotherapy is not uniformly used. In this retrospective cohort study, we ass...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Gynecol Oncol
Autors principals: Schlappe, Brooke A., Mueller, Jennifer J., Zivanovic, Oliver, Gardner, Ginger J., Roche, Kara Long, Sonoda, Yukio, Chi, Dennis S., O’Cearbhaill, Roisin E.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4917455/
https://ncbi.nlm.nih.gov/pubmed/27189456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2016.05.015
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars